US89422G1076
US89422G1076
Travere Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 490.728.000 | 233.175.000 | 110.5% |
| Cost of Revenue | 10.339.000 | 7.744.000 | 33.5% |
| Gross Profit | 480.389.000 | 225.431.000 | 113.1% |
| 543.213.000 | 546.820.000 | 0.7% | |
| Operating Income | -62.824.000 | -321.389.000 | 80.5% |
| Pretax Income | -49.273.000 | -320.510.000 | 84.6% |
| Net Income Common Stockholders | -25.546.000 | -321.545.000 | 92.1% |
| -- | -- | -- | |
| -- | -- | -- |